Karnataka raises concerns about a significant gap between the “landing cost” of drugs and the maximum retail price (MRP) charged at hospitals, with reported differences reaching up to 52.6 times for some medicines. The state asks the Centre to intervene, arguing that the pricing spread affects affordability and transparency for patients.
The report describes the issue as a gap in drug pricing from the point medicines arrive to the price they are ultimately sold at healthcare facilities. While the specific mechanisms behind the differences are not detailed in the available excerpt, the state’s concern centers on whether the current pricing framework allows excessive markups or inconsistencies. Karnataka’s move is presented as a request for federal-level review or action.
As only one outlet is provided here, differing angles across sources cannot be assessed. However, the core focus is consistent: Karnataka highlights unusually high cost-to-MRP differences and seeks central government attention to address them.
